Carlsmed Inc 주요 수익원은 Aprevo이며, 최신 수익 발표에서 수익은 27,165,000입니다. 지역별로는 United States이 Carlsmed Inc의 주요 시장이며, 수익은 27,165,000입니다.
Carlsmed Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Carlsmed Inc의 순손실은 $-60입니다.
Carlsmed Inc에 부채가 있나요?
예, Carlsmed Inc의 부채는 31입니다.
Carlsmed Inc의 발행 주식은 몇 주인가요?
Carlsmed Inc의 총 발행 주식은 27주입니다.
주요 통계
이전 종가
$9.63
시가
$9.61
일일 범위
$9.36 - $9.86
52주 범위
$8.86 - $17.19
거래량
24.9K
평균 거래량
122.3K
배당수익률
--
EPS(TTM)
-1.20
시가총액
$260.0M
CARL란 무엇인가요?
Carlsmed, Inc. engages in the development of AI based technology solutions to the medical industry. The company is headquartered in Carlsbad, California and currently employs 127 full-time employees. The company went IPO on 2025-07-23. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights intended to improve the digital surgical planning process. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.